Plasma homovanillic acid and prolactin in systemic lupus erythematosus

Abstract

Prolactin (PRL) is an important immunoregulator and might have a role in the pathogenesis of systemic lupus erythematosus (SLE). The regulation of pituitary prolactin secretion is complex and involves a negative feedback process in the hypothalamus, in which dopamine plays the principal role. However, the main source of serum prolactin in lupus patients is still not clearly established. Since homovanillic acid (HVA), the principal metabolite of dopamine (DA), is removed from the brain into the blood, it would indirectly reflect DA metabolism. It is assumed that the turnover of a neurotransmitter can be determined through an analysis of its metabolites. The objective of this study was to analyse plasma samples from SLE patients to see if there were any alterations in neurally functioning DA through its principal metabolite, HVA. We also measured the levels of PRL and compared HVA and PRL with the clinical activity of the disease. Twenty-four SLE patients and fifteen healthy controls were studied. The investigation was done over a period of 3 months.

The results of this study show significantly low levels of HVA in lupus patients compared to controls (P < 0.0001). This corresponds to a decrease in dopamine turnover. Hyperprolactinemia was observed in nine patients, and the average level of prolactin in lupus patients was higher than in healthy controls (P < 0.001). For the duration of the study, a significant percentage of variation was observed in the levels of HVA in the clinically active patients (P < 0.05) compared to inactive patients. When PRL was compared in these groups, throughout the study, no signifcant percentage of variation was observed. The relationship between HVA and PRL in healthy controls was r = 0.47, P=0.08, and in patients was r = 0.04, P = 0.84. It is suggested that there is a probable association between plasma levels of HVA and PRL in the healthy controls and not in the SLE patients.

Keywords

prolactin systemic lupus erythematosus homovanillic acid

Get full access to this article

View all access options for this article.

References

Reichlin S . Neuroendocrine-immune interactions . N Engl J Med 1993; 329: 1246–1253 .

Blalock JE . The syntax of immune-neuroendocrine communication . Immunol Today 1994; 15: 504–511 .

Ader R , Cohen N , Felten D . Psychoneuroimmunology: interactions between central nervous system and immune system . Lancet 1995; 345: 99–103 .

Deleplanque B , Vitiello S , Le Moal M , Neveu PJ . Modulation of immune reactivity by unilateral strial and mesolimbic dopaminergic lesions . Neurosci Lett 1994, 166: 216–220 .

Madden KS , Sanders VM , Felten DL . Catecholamine influences and sympathetic neural modulation of immune responsiveness . Annu Rev Pharmacol Toxicol 1995; 35: 417–448 .

Lavalle C et al. Correlaction study between prolactin and androgens in male patients with systemic lupus erythematosus . J Rheumatol 1987; 14: 268–272 .

Jara LJ , Lavalle C , Espinoza LR . Does prolactin have a role in pathogenesis of systemic lupus erythematosus . J Rheumatol 1992; 19: 1333–1336 .

McMurray RW et al. Long standing hyperprolactinemia associated with systemic lupus erythematosus: possible hormonal stimulation of an autoimmune disease . J Rheumatol 1994; 21: 843–850 .

McMurray RW et al. Prolactin influences autoimmune disease activity in the female B/W mouse . J Immunol 1991; 147: 3780–3787 .

10.

Müller EE , Nistico Á G . Neurotransmitter Regulation of the Anterior Pituitary. In: Müller EE , Nistico Á G , (eds). Brain messengers and the pituitary. Academic Press Inc.: USA , 1989: 404–537.

11.

Webster RA . Neurotransmitters pathways and release. In: Webster RA , Jordan CC , (eds.) Neurotransmitters, drugs and disease. 1st ed. Blackwell Scientific publications: Oxford , 1989: 31–47.

12.

Sternberg DE , Heninger GR , Roth RH . Plasma homovanillic acid as an index of brain dopamine metabolism: enhancement with debrisoquin . Life Sci 1983; 32: 2447–2452 .

13.

Kopin IJ . Catecholamines metabolism: basic aspects and clinical significance . Pharmacol Rev 1985; 37: 333–364 .

14.

Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271–1277 .

15.

Liang MH , Socher SA , Robets WN , Esdaile JM . Measurement of systemic lupus erythematosus activity in clinical research . Arthritis Rheum 1988; 31: 817–825 .

16.

Hay EM , Gordon C , Emery P . Assessment of lupus: where are we now? Ann Rheum Dis 1993; 52: 169–172 .

17.

Chang WH , Scheinin M , Burns, Linnoila M . Rapid and simple determination of homovanilic acid in plasma using high performance liquid chromatography with electrochemical detection . Acta Pharmacol Toxicol 1983; 53: 275–279 .

18.

Jara LJ et al. Hyperprolactinemia in systemic lupus erythematosus: association with disease activity . Am J Med Sci 1992; 303: 222–226 .

19.

Walker SE , Allen SH , Hoffman RW , McMurray RW . Prolactin: a stimulator of disease activity in systemic lupus erythematosus . Lupus 1995; 4: 3–9 .

20.

Ostendorf B et al. Hyperprolactinemia in systemic lupus erythematosus? Scand J Rheumatol 1996; 25: 97–102 .

21.

Buskila D et al. No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus . J Rheumatol 1996; 23: 629–632 .

22.

Miyai K , Ichihar K , Kondo K , Mori S . Asymptomatic hyperprolactinemia and prolactinoma in general population—Mass screening by paired assays of serum prolactin . Clin Endocrinol 1986; 25: 549–554 .

23.

Molitch ME . Pathologic hyperprolactinemia . Endo Metab Clin NA 1992; 21: 877–901 .

24.

Ferreira C et al. Instability of natural antibody repertoires in systemic lupus erythematosus patients, revealed by multiparametric analysis of serum antibody reactivities . Scand J Immunol 1997; 45: 331–341 .

25.

Reber PM . Prolactin and immunomodulation . Am J Med 1993; 95: 637–644 .

26.

Joffe T et al. Alternate-day corticosteroid treatment, mood and plasma HVA in patients with systemic lupus erythematosus . Neuropsycho-biology 1988; 19: 17–19 .

27.

Wolkowitz O et al. Dexamethasone increases plasma HVA but not MHPG in normal humans . Psychiatry Res 1985; 16: 102–109 .

28.

Clark C , Bailey A . Neurological and psychiatric signs associated with systemic lupus erythematosus . JAMA 1956; 160: 455–457 .

29.

Ferreira C , Rocha P , Fiúza T , Maltës F . Systemic lupus erythematosusclinical course and life events . Lupus 1995; 4: Suppl 2: 172-172 (abstract).

30.

Young LT et al. Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder . Bio-Psychiatry 1994; 35: 121–127 .

31.

Devanand D , Bowers M Jr , Hoffman F Jr , Nelson J . Elevated plasma homovanillic acid in depressed females with melancholia and psychosis . Psychiatry Res 1985; 15: 1–4 .

32.

Simpkins JW , Hodson CA , Kalra PS , Kalra SP . Chronic hyperprolactinemia depletes hypothalamic dopamine concentrations in male rats . Life Sci. 1982; 30: 1349–1353 .

33.

Morgan W , Herbert D , Pfeil K . The effect of hypophysectomy and subsequent prolactin replacement or of elevated prolactin alone on median eminence noradrenaline and dopamine in the rat . Endocrinology 1982; 110: 1584–1591 .

34.

Jara LJ , Prasad C , Espinoza LR . Elevated serum levels of cyclo (His-Pro), an endogenous inhibitor of pituitary prolactin secretion, in systemic lupus erythematosus patients . Lupus 1997; 6: 258–260 .

35.

Demarest K , McKay D , Riegle G , Moore K . Biochemical indices of tuberoinfundibular dopaminergic neuronal activity during lactation: a lack of response to prolactin . Neuroendocrinology 1983; 36: 130–137 .